Anika Therapeutics Q1 revenue rises 13%

Anika Therapeutics

29/04/2026 12:22

Overview

US osteoarthritis solutions firm's Q1 revenue rose 13% yr/yr, driven by both channels

Gross margin improved to 64.2%, up 8 points yr/yr on operational execution and product mix

Company completed $15 mln share repurchase under 10b5-1 plan

Outlook

Anika maintains 2026 revenue guidance at $114 mln to $122.5 mln, up 1% to 9% yr/yr

Company expects 2026 Commercial Channel revenue of $53 mln to $58 mln, up 10% to 20% yr/yr

OEM Channel revenue seen at $61 mln to $64.5 mln, flat to modestly lower yr/yr

Result Drivers

COMMERCIAL CHANNEL GROWTH - Regenerative Solutions revenue rose 20% yr/yr, driven by 35% US procedure growth for Integrity and increased surgeon adoption

OEM CHANNEL ORDER TIMING - OEM channel revenue rose 14% yr/yr, helped by favorable order timing and continued Monovisc demand

Company press release: ID:nGNXS6k8m

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$29.61 mln
$28.14 mln (2 Analysts)
Q1 Adjusted EPS
Beat
$0.27
-$0.16 (2 Analysts)
Q1 Net Income
-$5.06 mln
Q1 Gross Profit
$19 mln
Q1 Income from Operations
-$5.49 mln
Q1 Pretax Profit
-$4.82 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Anika Therapeutics Inc is $17.50, about 14.7% above its April 28 closing price of $15.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)